City Therapeutics (NASDAQ: CTY) is set to price its IPO this week, marketing 9.72 million shares at $17 to $19 apiece. At the top of the range, the deal raises $184.7 million and values the company at up to $956.3 million.

‍

That's nearly $1 billion for a company founded in 2023, with no product sales and one drug in early human testing.

‍

But the drug isn't really what you're being asked to pay for.

‍

Why the price tag looks the way it does

‍

City develops RNA interference (RNAi) drugs. Put simply, these medicines switch off the genetic instructions a cell uses to build a specific harmful protein, so the protein never gets made.

‍

That's not a new idea. Alnylam Pharmaceuticals (NASDAQ: ALNY) spent years turning RNAi from a lab concept into approved, commercial medicines. And John Maraganore, Alnylam's founding CEO, is City's executive chair. CEO Andrew Orth is an Alnylam veteran as well.

‍

So here's the cleanest way to read this deal. You're not buying a drug. You're buying a team that has already built an RNAi business once, betting it can do it again.

‍

Worth noting: the early money is staying put. ARCH Venture Partners owns about 35% of City heading into the listing and Fidelity holds roughly 10%. The offering is made up entirely of new shares, which means none of the existing backers are cashing out here.

‍

Those backers have put in more than $230 million so far, including a $135 million Series A in October 2024 and a $99.5 million Series B in June.

‍

What City is actually testing

‍

The lead drug, CITY-FXI, targets Factor XI. That's a clotting protein, and the hope is that blocking it prevents dangerous clots with less bleeding risk than today's blood thinners.

‍

CITY-FXI entered a Phase 1 trial in healthy volunteers this year, and early dose groups showed Factor XI levels falling as the dose went up. More Phase 1 data is due in late 2026.

‍

Behind it sit programs for Stargardt disease (an inherited eye disease that causes vision loss in children and young adults) and for anemia tied to chronic illness. City also has partnerships with Bausch + Lomb (NYSE: BLCO) and Biogen (NASDAQ: BIIB), and booked about $14 million in revenue over the 12 months ended June 30 from collaboration work, not drug sales.

‍

Indeed, the market is clearly willing to pay up for this corner of biotech. Fellow RNAi developer ADARx Pharmaceuticals (NASDAQ: ADRX) upsized its IPO last month and priced it at the top of its range, raising $446.3 million. And City is asking for a higher valuation than Iambic Therapeutics, an AI drug developer pricing the same week at up to $805.8 million, even though Iambic brought in more revenue (about $18 million) over the same 12 months.

‍

For the valuation to hold up from here, a few things have to go right:

‍

- Phase 1 data later this year has to confirm the early signal

- A second program needs to reach the clinic on schedule

- City has to show its newer RNAi designs work beyond the liver

- Bausch + Lomb and Biogen have to stay committed
‍

The risk is in the price


To be sure, pedigree doesn't get a drug through clinical trials. CITY-FXI has only been tested in healthy volunteers, which shows the drug does what it's designed to do in the body, not that it prevents clots in sick patients. Factor XI is also one of the more crowded races in heart and blood medicine, with much larger drugmakers already in late-stage trials.

‍

Make no mistake: at close to $1 billion, a lot of future success is already baked in.

‍

If you're watching CTY's debut, the number that matters isn't the first-day move. It's the Phase 1 update due before year-end. That's the first real test of whether the Alnylam playbook works a second time.

‍